Trial Now Recruiting: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (NCT07070232)

WHY IT MATTERS

This trial is actively recruiting patients with advanced solid tumors across multiple sites, offering access to a novel immunotherapy approach from BioNTech before it becomes widely available.

Researchers are testing a new experimental cancer treatment called BNT326 to see if it is safe and works well for people with advanced solid tumors (cancers that have spread or come back after treatment). The study will first test BNT326 alone, then test it combined with other experimental treatments. About 980 people will participate in this Phase 1 and Phase 2 trial.

NCT ID: NCT07070232 Status: RECRUITING Conditions: Advanced Solid Tumor Phase: PHASE1, PHASE2 Enrollment: 980 Sponsor: BioNTech SE Summary: This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

YOU CAN ACT ON THIS

If you have advanced solid tumors with no other treatment options, check if you meet eligibility criteria and contact the trial coordinator at clinicaltrials.gov using NCT07070232 to learn about enrollment at sites near you.